DNPUF - Nabriva antibiotic meets primary endpoint in phase 3 trial; shares soar 40%

Nabriva Therapeutics (NBRV) and Sinovant Sciences' antibiotic lefamulin was non-inferior to moxifloxacin in a phase 3 study, according to top-line results.The randomized, double-blind study in 125 patients with community acquired bacterial pneumonia compared the efficacy and safety of IV/oral lefamulin to IV/oral moxifloxacin.In a modified intent to treat (mITT) population, the clinical response success rates were 76.8% for lefamulin and 71.4% for mixofloxacin.Also, Sinovant inked an agreement with a Chinese subsidiary of Sumitomo Dainippon Pharma (DNPUF) to acquire development and commercialization rights for lefamulin in China. Nabriva shares are up 40.5% to $2.08 in after-hours trading.

For further details see:

Nabriva antibiotic meets primary endpoint in phase 3 trial; shares soar 40%